APA citiranje

Ahluwalia, M., Peereboom, D., Schilero, C., Forst, D., Wong, E., Wen, P., & Reardon, D. (2018). RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA. Neuro Oncol.

Citação norma Chicago

Ahluwalia, Manmeet, David Peereboom, Cathy Schilero, Deborah Forst, Eric Wong, Patrick Wen, and David Reardon. "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA." Neuro Oncol 2018.

MLA citiranje

Ahluwalia, Manmeet, et al. "RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA." Neuro Oncol 2018.